how does semaglutide lower a1c Hemoglobin Reduction With the GLP-1 Receptor Agonist Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs What is Ozempic® Pen? |

[2] [8] However, the agency noted they cannot definitively rule out that a small risk may exist and continues to review incoming safety reports through the FDA Adverse Event Reporting System (FAERS) and other surveillance mechanisms

The FDA-approved maximum for weight loss is 2.4 mg weekly (Wegovy)

2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors

Sierra et al., 2007

Noguchi K et al